The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso
Open accessAbstract
El síndrome hemolítico urémico (SHU) es una entidad clínica definida por la tríada anemia hemolítica no inmune, trombocitopenia e insuficiencia renal aguda, en la que las lesiones subyacentes están mediadas por un proceso de microangiopatía trombótica (MAT) sistémico. Distintas causas pueden desencadenar el proceso de MAT que caracteriza el SHU. En este documento consideramos SHU atípico (SHUa) como el subtipo de SHU en el que los fenómenos de MAT son fundamentalmente consecuencia del daño producido en el endotelio de la microvasculatura renal y de otros órganos por desregulación de la actividad del sistema del complemento. En los últimos años se han identificado diversas mutaciones en genes del sistema del complemento asociados a SHUa, que explicarían aproximadamente el 60% de los casos de SHUa, y se han caracterizado funcionalmente numerosas mutaciones y polimorfismos asociados a SHUa que han permitido determinar que la patología se produce como consecuencia de la deficiente regulación de la activación del complemento sobre las superficies celulares y que lleva al daño endotelial mediado por la activación del C5 y de la vía terminal del complemento. Eculizumab es un anticuerpo monoclonal humanizado que inhibe la activación del C5, bloqueando la generación de la molécula proinflamatoria C5a y la formación del complejo de ataque de membrana. En estudios prospectivos en pacientes con SHUa su administración ha demostrado la interrupción rápida y sostenida del proceso de MAT, con una mejora significativa de la función renal a largo plazo y una reducción importante de la necesidad de diálisis y el cese de la terapia plasmática. En función de las evidencias científicas publicadas y la experiencia clínica acumulada, el Grupo Español de SHUa publicamos un documento de consenso con recomendaciones para el tratamiento de la enfermedad (Nefrología 2013;33(1):27-45). En la presente versión online del documento se actualizan los contenidos sobre la clasificación etiológica de las MAT, la fisiopatología del SHUa, su diagnóstico diferencial y su manejo terapéutico. Haemolytic uraemic syndrome (HUS) is a clinical entity defined as the triad of nonimmune haemolytic anaemia, thrombocytopenia, and acute renal failure, in which the underlying lesions are mediated by systemic thrombotic microangiopathy (TMA). Different causes can induce the TMA process that characterizes HUS. In this document we consider atypical HUS (aHUS) a sub-type of HUS in which the TMA phenomena are the consequence of the endotelial damage in the microvasculature of the kidneys and other organs due to a disregulation of the activity of the complement system. In recent years, a variety of aHUs-related mutations have been identified in genes of the the complement system, which can explain approximately 60% of the aHUS cases, and a number of mutations and polymorphisms have been functionally characterized. These findings have stablished that aHUS is a consequence of the insufficient regulation of the activiation of the complement on cell surfaces, leading to endotelial damage mediated by C5 and the complement terminal pathway. Eculizumab is a monoclonal antibody that inhibits the activation of C5 and blocks the generation of the pro-inflammatory molecule C5a and the formation of the cell membrane attack complex. In prospective studies in patients with aHUS, the use of Eculizumab has shown a fast and sustained interruption of the TMA process and it has been associated with significative long-term improvements in renal function, the interruption of plasma therapy and important reductions in the need of dialysis. According to the existing literature and the accumulated clinical experience, the Spanish aHUS Group published a consensus document with recommendations for the treatment of aHUs (Nefrologia 2013;33[1]:27-45). In the current online version of this document, we update the aetiological classification of TMAs, the pathophysiology of aHUS, its differential diagnosis and its therapeutic management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Syndromes of Thrombotic Microangiopathy
George, J. N., & Nester, C. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1312353 · Cited by 1,279
Noris, M., Caprioli, J., Bresin, E., Mossali, C., Pianetti, G., Gamba, S., Daina, E., Fenili, C., Castelletti, F., Sorosina, A., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02210310 · Cited by 1,042
Furlan, M., Robles, R., & Lamie, B. (1996) · Blood · doi:10.1182/blood.v87.10.4223.bloodjournal87104223 · Cited by 895
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778
Caprioli, J., Noris, M., Brioschi, S., Pianetti, G., Castelletti, F., Bettinaglio, P., Mele, C., Bresin, E., Cassis, L., Gamba, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-007252 · Cited by 732
Atypical hemolytic uremic syndrome
Loirat, C., & Frémeaux-Bacchi, V. (2011) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-6-60 · Cited by 669
Thrombomodulin Mutations in Atypical Hemolytic–Uremic Syndrome
Delvaeye, M., Noris, M., De Vriese, A., Esmon, C. T., Esmon, N. L., Ferrell, G., Del-Favero, J., Plaisance, S., Claes, B., Lambrechts, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810739 · Cited by 554
Anti–Factor H Autoantibodies Associated with Atypical Hemolytic Uremic Syndrome
Dragon-Durey, M.-A. G. A., Loirat, C., Cloarec, S., Macher, M.-A., Blouin, J., Nivet, H., Weiss, L., Fridman, W. H., & Frémeaux-Bacchi, V. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004050380 · Cited by 502
Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome
Lemaire, M., Frémeaux-Bacchi, V., Schaefer, F., Choi, M., Tang, W. H., Le Quintrec, M., Fakhouri, F., Taque, S., Nobili, F., Martinez, F., et al. (2013) · Nature Genetics · doi:10.1038/ng.2590 · Cited by 483
Mutations in Complement Factor I Predispose to Development of Atypical Hemolytic Uremic Syndrome
Kavanagh, D., Kemp, E. J., Mayland, E., Winney, R. J., Duffield, J. S., Warwick, G., Richards, A., Ward, R., Goodship, J. A., & Goodship, T. H. J. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005010103 · Cited by 475
Pregnancy-Associated Hemolytic Uremic Syndrome Revisited in the Era of Complement Gene Mutations
Fakhouri, F., Roumenina, L., Provot, F., Sallée, M., Caillard, S., Couzi, L., Essig, M., Ribes, D., Dragon-Durey, M.-A., Bridoux, F., et al. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070706 · Cited by 467
de Jorge, E. G., Harris, C. L., Esparza-Gordillo, J., Carreras, L., Arranz, E. A., Garrido, C. A., López-Trascasa, M., Sánchez-Corral, P., Morgan, B. P., & de Córdoba, S. R. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603420103 · Cited by 447
Richards, A., Kemp, E. J., Liszewski, M. K., Goodship, J. A., Lampe, A. K., Decorte, R., Müslümanogğlu, M. H., Kavukcu, S., Filler, G., Pirson, Y., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2135497100 · Cited by 405
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome
Frémeaux-Bacchi, V., Miller, E. C., Liszewski, M. K., Strain, L., Blouin, J., Brown, A. L., Moghal, N., Kaplan, B. S., Weiss, R. A., Lhotta, K., et al. (2008) · Blood · doi:10.1182/blood-2008-01-133702 · Cited by 372
Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome
The European Paediatric Study Group for HUS, Ariceta, G., Besbas, N., Johnson, S., Karpman, D., Landau, D., Licht, C., Loirat, C., Pecoraro, C., Taylor, C. M., et al. (2009) · Pediatric Nephrology · doi:10.1007/s00467-008-0964-1 · Cited by 352
Self-citationBresin, E., Rurali, E., Caprioli, J., Sanchez-Corral, P., Fremeaux-Bacchi, V., Rodriguez de Cordoba, S., Pinto, S., Goodship, T. H. J., Alberti, M., Ribes, D., et al. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012090884 · Cited by 352
Eculizumab for Atypical Hemolytic–Uremic Syndrome
Nürnberger, J., Philipp, T., Witzke, O., Saez, A. O., Vester, U., Baba, H. A., Kribben, A., Zimmerhackl, L. B., Janecke, A. R., Nagel, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0808527 · Cited by 346
Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome
Fremeaux-Bacchi, V, Dragon-Durey, M.-A., Blouin, J., Vigneau, C., Kuypers, D., Boudailliez, B., Loirat, C., Rondeau, E., & Fridman, W. H. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2004.019083 · Cited by 339
Richards, A., Buddles, M. R., Donne, R. L., Kaplan, B. S., Kirk, E., Venning, M. C., Tielemans, C. L., Goodship, J. A., & Goodship, T. H. J. (2001) · The American Journal of Human Genetics · doi:10.1086/318203 · Cited by 310
Maga, T. K., Nishimura, C. J., Weaver, A. E., Frees, K. L., & Smith, R. J. H. (2010) · Human Mutation · doi:10.1002/humu.21256 · Cited by 308
Caprioli, J., Castelletti, F., Bucchioni, S., Bettinaglio, P., Bresin, E., Pianetti, G., Gamba, S., Brioschi, S., Daina, E., Remuzzi, G., et al. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg363 · Cited by 306
Pérez-Caballero, D., González-Rubio, C., Gallardo, M. E., Vera, M., López-Trascasa, M., Rodríguez de Córdoba, S., & Sánchez-Corral, P. (2001) · The American Journal of Human Genetics · doi:10.1086/318201 · Cited by 293
Self-citationDe Córdoba, S. R., & De Jorge, E. G. (2007) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2007.03552.x · Cited by 287
CAPRIOLI, J., BETTINAGLIO, P., ZIPFEL, P. F., AMADEI, B., DAINA, E., GAMBA, S., SKERKA, C., MARZILIANO, N., REMUZZI, G., & NORIS, M. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v122297 · Cited by 286
Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria
Kelly, R. J., Höchsmann, B., Szer, J., Kulasekararaj, A., de Guibert, S., Röth, A., Weitz, I. C., Armstrong, E., Risitano, A. M., Patriquin, C. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502950 · Cited by 286
Esparza-Gordillo, J., Jorge, E. G. D., Buil, A., Berges, L. C., López-Trascasa, M., Sánchez-Corral, P., & Córdoba, S. R. D. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi066 · Cited by 281
Besbas, N., Karpman, D., Landau, D., Loirat, C., Proesmans, W., Remuzzi, G., Rizzoni, G., Taylor, C. M., Van de Kar, N., & Zimmerhackl, L. B. (2006) · Kidney International · doi:10.1038/sj.ki.5001581 · Cited by 277
Eculizumab for Congenital Atypical Hemolytic–Uremic Syndrome
Gruppo, R. A., & Rother, R. P. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0809959 · Cited by 275
Le Quintrec, M., Zuber, J., Moulin, B., Kamar, N., Jablonski, M., Lionet, A., Chatelet, V., Mousson, C., Mourad, G., Bridoux, F., et al. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12077 · Cited by 268
Pathophysiology of thrombotic thrombocytopenic purpura
Tsai, H.-M. (2010) · International Journal of Hematology · doi:10.1007/s12185-009-0476-1 · Cited by 245
Bu, F., Maga, T., Meyer, N. C., Wang, K., Thomas, C. P., Nester, C. M., & Smith, R. J. H. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013050453 · Cited by 242
Józsi, M., Strobel, S., Dahse, H.-M., Liu, W.-S., Hoyer, P. F., Oppermann, M., Skerka, C., & Zipfel, P. F. (2007) · Blood · doi:10.1182/blood-2007-02-071472 · Cited by 233
Verhoef, G., Johnsen, H. E., Rossi, F. G., Salar, A., Hamilton, L., Schoonen, W. M., Pujol, B., & Duhrsen, U. (2008) · Blood · doi:10.1182/blood.v112.11.4948.4948 · Cited by 233
Fremeaux-Bacchi, V. A. A., Moulton, E. A., Kavanagh, D., Dragon-Durey, M.-A. G. A., Blouin, J., Caudy, A., Arzouk, N., Cleper, R., Francois, M., Guest, G., et al. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005101051 · Cited by 229
Thrombotic microangiopathy after renal transplantation in the United States
Reynolds, J. C., Agodoa, L. Y., Yuan, C. M., & Abbott, K. C. (2003) · American Journal of Kidney Diseases · doi:10.1016/j.ajkd.2003.07.008 · Cited by 219
Abarrategui-Garrido, C., Martínez-Barricarte, R., López-Trascasa, M., Rodríguez de Córdoba, S., & Sánchez-Corral, P. (2009) · Blood · doi:10.1182/blood-2009-05-223834 · Cited by 206
Self-citationComplement and the atypical hemolytic uremic syndrome in children
Loirat, C., Noris, M., & Frémeaux‐Bacchi, V. (2008) · Pediatric Nephrology · doi:10.1007/s00467-008-0872-4 · Cited by 206
Ardissino, G., Testa, S., Possenti, I., Tel, F., Paglialonga, F., Salardi, S., Tedeschi, S., Belingheri, M., & Cugno, M. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.01.434 · Cited by 201
Eculizumab for the treatment of preeclampsia/HELLP syndrome
Burwick, R. M., & Feinberg, B. B. (2013) · Placenta · doi:10.1016/j.placenta.2012.11.014 · Cited by 196
New insights into postrenal transplant hemolytic uremic syndrome
Zuber, J., Le Quintrec, M., Sberro-Soussan, R., Loirat, C., Frémeaux-Bacchi, V., & Legendre, C. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.155 · Cited by 196
Atypical Haemolytic Uraemic Syndrome Associated with a Hybrid Complement Gene
Venables, J. P., Strain, L., Routledge, D., Bourn, D., Powell, H. M., Warwicker, P., Diaz-Torres, M. L., Sampson, A., Mead, P., Webb, M., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030431 · Cited by 195
Bienaime, F., Dragon-Durey, M.-A., Regnier, C. H., Nilsson, S. C., Kwan, W. H., Blouin, J., Jablonski, M., Renault, N., Rameix-Welti, M.-A., Loirat, C., et al. (2010) · Kidney International · doi:10.1038/ki.2009.472 · Cited by 192
Liver-Kidney Transplantation to Cure Atypical Hemolytic Uremic Syndrome
Saland, J. M., Ruggenenti, P., & Remuzzi, G. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008080906 · Cited by 165
Roumenina, L. T., Jablonski, M., Hue, C., et al. (2009) · Blood · doi:10.1182/blood-2009-01-197640 · Cited by 157
Mutations in complement C3 predispose to development of atypical haemolytic uraemic syndrome
Frémeaux‐Bacchi, V., Goodship, T. H. J., Régnier, C. H., Dragon‐Durey, M., Janssen, B. J. C., & Atkinson, J. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.038 · Cited by 153
DGKE Variants Cause a Glomerular Microangiopathy That Mimics Membranoproliferative GN
Özaltın, F., Li, B., Rauhauser, A. A., An, S.-W., Söylemezoğlu, O., Gönül, İ. I., Taşkıran, E. Z., Ibsirlioglu, T., Korkmaz, E., Bilginer, Y., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012090903 · Cited by 153
Dragon‐Durey, M., Blanc, C., Marliot, F., Loirat, C., Blouin, J., Sautès‐Fridman, C., Fridman, W. H., & Frémeaux‐Bacchi, V. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.064766 · Cited by 152
Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome
Mache, C. J., Acham‐Roschitz, B., Frémeaux‐Bacchi, V., Kirschfink, M., Zipfel, P. F., Rödl, S., Vester, U., & Ring, E. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01090209 · Cited by 148
Drug-Induced Thrombotic Microangiopathy: Incidence, Prevention and Management
Pisoni, R., Ruggenenti, P. L., & Remuzzi, G. (2001) · Drug Safety · doi:10.2165/00002018-200124070-00002 · Cited by 140
Esparza-Gordillo, J., de Jorge, E. G., Abarrategui-Garrido, C., CARRERAS, L., López‐Trascasa, M., Sánchez‐Corral, P., & de Córdoba, S. R. (2006) · Molecular Immunology · doi:10.1016/j.molimm.2005.11.008 · Cited by 131
Predictors of Fatality in Postdiarrheal Hemolytic Uremic Syndrome
Oakes, R. S., Siegler, R. L., McReynolds, M. A., Pysher, T. J., & Pavia, A. T. (2006) · PEDIATRICS · doi:10.1542/peds.2005-0785 · Cited by 127
Johnson, S. A., Stojanović, J., Ariceta, G., Bitzan, M. M., Beşbaş, N., Frieling, M. L., Karpman, D., Landau, D., Langman, C. B., Licht, C. P. B., et al. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2817-4 · Cited by 120
Self-citationHemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder
Sharma, A. P., Greenberg, C. R., Prasad, A. N., & Prasad, C. (2007) · Pediatric Nephrology · doi:10.1007/s00467-007-0604-1 · Cited by 116
Robson, M. G., Côté, I., Abbs, I. A., et al. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00051.x · Cited by 113
Disseminated Intravascular Coagulation: What's New?
Levi, M. M. (2005) · Critical Care Clinics · doi:10.1016/j.ccc.2005.02.001 · Cited by 104
Plasmatherapy in Atypical Hemolytic Uremic Syndrome
Loirat, C., Garnier, A., Leclerc, A.-L. S., et al. (2010) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0030-1262890 · Cited by 102
Management of hemolytic uremic syndrome
Loirat, C., Saland, J. M., & Bitzan, M. M. (2012) · La Presse Médicale · doi:10.1016/j.lpm.2011.11.013 · Cited by 102
An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document
Campistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyo, J. M., Macia, M. L., Mendizábal, S., Praga, M., et al. (2015) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2015.11.006 · Cited by 100
Self-citationEculizumab in Acute Recurrence of Thrombotic Microangiopathy After Renal Transplantation
Hadaya, K., Ferrari‐Lacraz, S., Fumeaux, D., Boehlen, F., Toso, C., Moll, S., Martin, P.-Y., & Villard, J. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03696.x · Cited by 91
Fakhouri, F., Delmas, Y., Provôt, F., Barbet, C., Karras, A., Makdassi, R., Courivaud, C., Rifard, K., Servais, A., Allard, C., et al. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.07.011 · Cited by 87
Loss of DGKε induces endothelial cell activation and death independently of complement activation
Bruneau, S., Néel, M., Roumenina, L. T., Frimat, M., Laurent, L., Frémeaux‐Bacchi, V., & Fakhouri, F. (2014) · Blood · doi:10.1182/blood-2014-06-579953 · Cited by 86
Eculizumab for Atypical Hemolytic Uremic Syndrome in Pregnancy
Ardissino, G., Ossola, M. W., Baffero, G. M., Rigotti, A., & Cugno, M. (2013) · Obstetrics and Gynecology · doi:10.1097/aog.0b013e31828e2612 · Cited by 75
Complement Mutations in Diacylglycerol Kinase-ε–Associated Atypical Hemolytic Uremic Syndrome
Chinchilla, D. S., Pinto, S., Höppe, B., Adragna, M. S., Lopez, L., Roldán, M. L. J., Peña, A., López‐Trascasa, M., Sánchez‐Corral, P., & de Córdoba, S. R. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01640214 · Cited by 72
Pandemic H1N1 influenza A infection and (atypical) HUS—more than just another trigger?
Allen, U., & Licht, C. P. B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-010-1690-z · Cited by 56
Quintrec, M. L., Zuber, J., Noël, L., Thervet, É., Frémeaux‐Bacchi, V., Fridman, W. H., Legendre, C., & Dragon‐Durey, M. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02586.x · Cited by 51
Guía diagnóstica y terapéutica de las microangiopatías trombóticas del Grupo Español de Aféresis
Contreras, E., de la Rubia, J., del Río-Garma, J., Díaz‐Ricart, M., Gala, J. M. G., & Lozano, M. (2014) · Medicina Clínica · doi:10.1016/j.medcli.2014.09.013 · Cited by 46
Carr, R. M., & Cataland, S. R. (2012) · Annals of Hematology · doi:10.1007/s00277-012-1622-z · Cited by 38
Alachkar, N., Bagnasco, S. M., & Montgomery, R. A. (2012) · Transplant International · doi:10.1111/j.1432-2277.2012.01497.x · Cited by 37
Preservation of Renal Function in Atypical Hemolytic Uremic Syndrome by Eculizumab: A Case Report
Giordano, M., Castellano, G., Messina, G., Divella, C., Bellantuono, R., Puteo, F., Colella, V., Depalo, T., & Gesualdo, L. (2012) · PEDIATRICS · doi:10.1542/peds.2011-1685 · Cited by 33
Serres, S. A. D., & Isenring, P. (2008) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfn687 · Cited by 29
Wilson, C. H., Torpey, N., Jaques, B. C., Strain, L., Talbot, D., Manas, D., & Goodship, T. H. J. (2011) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2011.04.008 · Cited by 22
Early treatment with eculizumab in atypical haemolytic uraemic syndrome
Garjau, M., Azancot, M. A., Ramos, R., Sánchez‐Corral, P., Montero, M. A., & Serón, D. (2012) · Clinical Kidney Journal · doi:10.1093/ndtplus/sfr157 · Cited by 21
Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group
Contreras, E., de la Rubia, J., del Río-Garma, J., Díaz‐Ricart, M., Gala, J. M. G., & Lozano, M. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2015.11.007 · Cited by 18
Eculizumab for atypical haemolytic uraemic syndrome: what next?
Fakhouri, F., & Frémeaux‐Bacchi, V. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.150 · Cited by 15
Greenbaum, L. A., Babu, S., Furman, R. R., Sheerin, N., Cohen, D. J., Gaber, A. O., Eitner, F., Delmas, Y., Loirat, C., Bedrosian, C. L., et al. (2011) · Blood · doi:10.1182/blood.v118.21.193.193 · Cited by 10
Fakhouri, F., Hourmant, M., Campistol, J. M., et al. (2013) · Open Repository and Bibliography (University of Liège) · Cited by 9
Self-citation
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Atypical Hemolytic–Uremic Syndrome
Noris, M., & Remuzzi, G. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0902814 · Cited by 1,338
International, F. H., Loirat, C., Fakhouri, F., Ariceta, G., Besbas, N., Bitzan, M., Bjerre, A., Coppo, R., Emma, F., Johnson, S., et al. (2016) · Pediatric Nephrology · doi:10.1007/s00467-015-3076-8 · Cited by 596
Self-citationLicht, C., Greenbaum, L. A., Muus, P., Babu, S., Bedrosian, C. L., Cohen, D. J., Delmas, Y., Douglas, K., Furman, R. R., Gaber, O. A., et al. (2015) · Kidney International · doi:10.1038/ki.2014.423 · Cited by 420
Fakhouri, F., Hourmant, M., Campistol, J. M., Cataland, S. R., Espinosa, M., Gaber, A. O., Menne, J., Minetti, E. E., Provôt, F., Rondeau, E., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.12.034 · Cited by 305
Self-citation
Metadata
- Authors
- Campistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyó, J. M., Macía, M., Mendizábal, S., Praga, M., Román, E., Torra, R., Valdés, F., Vilalta, R., & Rodríguez de Córdoba, S.
- Venue
- Nefrología
- Publisher
- Elsevier BV
- Published
- 2015-09
- Volume
- 35
- Issue
- 5
- Pages
- 421-447
- ISSN
- 0211-6995 (ISSN-L)
- OpenAlex
- W2159884188
- Cited by
- 272
- References
- 79
- FWCI
- 13.33
- Type
- journal article
- Language
- es
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.